Objectives Previous cost-effectiveness analyses of oxaliplatin have been based on randomised trials whereas current Dutch policy requires evidence from daily practice. The objective of this study was to examine the real-world cost-effectiveness of oxaliplatin plus fluoropyrimidines (FL) versus FL-only as adjuvant treatment of stage III colon cancer. Methods A Markov model was developed to estimate lifetime cost and quality-adjusted life-years from a hospital perspective. The effectiveness of the oxaliplatin arm was modelled by combining published efficacy data from the pivotal clinical registration trial (MOSAIC trial) with realworld (RW) data from a Dutch population-based observational study. RW patients were categorised into ''eligible'' or ''ineligible'', depending on whether the patients fulfilled the MOSAIC trial eligibility criteria. Ineligible RW patients (18 %) had a poorer prognosis than eligible RW patients (82 %) and MOSAIC trial patients. The effectiveness of the comparator was modelled using MOSAIC trial results. All cost inputs were based on RW patients and reported in Euro 2012. Cost-effectiveness analyses were performed for four different scenarios: (1) cost-effectiveness analyses based on MOSAIC trial patients; (2) costeffectiveness analyses using MOSAIC and eligible RW patients; (3) cost-effectiveness analyses using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had an equal effect in ineligible and eligible patients; (4) cost-effectiveness analyses using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had no effect amongst ineligibles. For each scenario, univariate and probabilistic sensitivity analyses were undertaken. Results MOSAIC trial patients and eligible RW patients treated with oxaliplatin had comparable 2-year disease-free survivals (79.5 vs. 78.4 %). Oxaliplatin showed an incremental QALY gain of 1.02, 1.13, 1.17 and 0.93 and incremental cost of €9,961, €11,055, €9,814 and €11,854 in scenarios 1-4, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were €9,766, €9,783, €8,388 and €12,746 in scenarios 1-4, respectively. In all scenarios, univariate and probabilistic sensitivity analyses indicated that the ICERs are acceptable and robust under a wide range of model assumptions. Conclusions The ICERs of the different scenarios that resulted from combining MOSAIC trial data with data from Dutch daily practice all suggest that FL ? oxaliplatin is cost-effective versus FL alone in the adjuvant treatment of colon cancer. This article illustrates how one could design and implement a real-world cost-effectiveness study to yield internally valid results that could also be generalisable.
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Introduction
Colon and rectal cancers are among the most common types of cancer in the western world with 215,000 deaths in Europe in 2012 [1] . Nearly half of the patients who undergo curative surgery will ultimately relapse and die of metastatic disease [2] . During the 1990s the survival rates of patients with stage III colon cancer significantly improved by the introduction of adjuvant chemotherapy with intravenous fluoropyrimidine, 5-fluorouracil, and leucovorin (5FU/LV) [3, 4] . In 2004, a large phase III clinical trial in colon cancer [Multicenter International Study of Oxaliplatin/5-Fluoroucacil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)] demonstrated that the addition of oxaliplatin to 5FU/LV significantly improved disease-free survival (DFS) compared to 5FU/LV alone. As a result, 6 months of oxaliplatin combined with 5FU/LV (FOLFOX) became the standard adjuvant treatment in the Netherlands for stage III colon cancer patients as of early 2005 [5] . Treatment with 5FU/ LV only remained indicated for patients who were not eligible or refused treatment with oxaliplatin. At that time the oral fluoropyrimidine capecitabine, alone or in combination with oxaliplatin (CAPOX), also became available as an alternative to 5FU/LV or FOLFOX, as these treatments were found to be equally effective in the treatment of stage III colon or metastatic colorectal cancer [6] [7] [8] [9] .
Next to oxaliplatin, many other expensive drugs have become available in the past decade, posing a substantial financial burden on the health care sector. In striking an optimal balance between ensuring timely access of these medicines and having sufficient evidence regarding its effectiveness and cost-effectiveness, Dutch policy regulations for expensive inpatient drugs have been implemented since 2006 [10, 11] . This policy enables new expensive medicine to be conditionally reimbursed for a period of four years without restriction. However, one important condition is that additional evidence, including evidence from Dutch daily practice, is required to assess appropriate use and to estimate the cost-effectiveness of the expensive drug in daily practice (real-world cost-effectiveness). The decision about whether or not to continue funding beyond the first 4 years will be mainly based on the real-world (RW) cost-effectiveness.
Currently, little is known about the use of real-world (RW) data in cost-effectiveness estimations of expensive medicines. For example, previous cost-effectiveness analyses (CEAs) of oxaliplatin have been solely based on randomised trials. [12] [13] [14] [15] [16] These results can substantially differ from RW cost-effectiveness results because differences between RCTs and daily practice may exist in patient selection criteria, dosing regiments, the use of supportive care and the intensity of follow-up [17] .
The aim of this study was to estimate the RW costeffectiveness of fluoropyrimidines (FL) plus oxaliplatin versus FL only, as adjuvant treatment of stage III colon cancer. These estimates were based on a combination of published MOSAIC trial data with data from a Dutch population-based observational study [5, 18] .
Methods

Data Sources
Two data sources were used to assess the RW cost-effectiveness of adding oxaliplatin to FL in patients with stage III colon cancer: the MOSAIC trial and a Dutch population-based observational study [5, [18] [19] [20] .
The MOSAIC trial was a multicentre international randomised controlled trial enrolling 2,246 patients with both stage II and III colon cancer. We examined the subgroup of 1,347 stage III patients of which 672 were randomised to adjuvant treatment with FL ? oxaliplatin and 675 to FL only. Since completion of the study, 3-year DFS as well as final results of this study including 6-year overall survival (OS) and 5-year updated DFS have been published [5, 19] .
The Dutch population-based observational study involved a retrospective analysis of the treatment outcomes of 391 stage III colon cancer patients diagnosed in 2005 and 2006. The study population was created by selecting a representative sample of 19 Dutch hospitals and then gathering RW data from the Dutch Cancer Registry and medical records of all patients treated in these 19 hospitals. Detailed methods of this study and its results regarding patient characteristics, chemotherapy use and 2-year DFS have been published [18, 20] .
In order to determine how to combine these two sources of evidence in a model, we first compared the two studies on the following subjects: (1) treatments, (2) patients and (3) disease-free and overall survival outcomes. An overview is provided in Table 1 . 
Treatments
In the MOSAIC trial, patients were randomised to receive FL only (n = 675) or FL ? oxaliplatin (n = 672). Although treatment choice was not fixed in the observational study, we found that also RW patients received FL only or FL ? oxaliplatin. Since treatment allocation was not randomised in these RW patients, the decision whether a patient was treated with FL only or FL ? oxaliplatin was left up to the judgement of the physicians. Specific reasons for not prescribing oxaliplatin were not often retrievable from patient records. In RW patients, FL ? oxaliplatin was prescribed more often than FL only (n = 281 versus n = 110, respectively).
Regarding the specific FL regimen used, all MOSAIC patients received 5FU/LV or FOLFOX. In RW practice more variation was seen. For FL-only treatment, oral capecitabine was most frequently used, with few patients receiving 5FU/LV. For FL ? oxaliplatin treatment, both FOLFOX (48 %) and CAPOX (52 %) regimens were prescribed in RW oxaliplatin patients. Dosages given in daily practice corresponded well to those seen in the MOSAIC trial [18] .
Patients
The target population of both studies consisted of patients diagnosed with stage III colon cancer who underwent curative surgery. In contrast to the Dutch observational study where no additional entrance criteria were used, the MOSAIC trial only enrolled patients who fulfilled certain eligibility criteria: patients had to start the treatment within 7 weeks after surgery, be younger than 75 years, and have a good performance score and low carcinoembryonic antigen (CEA) value (Table 1 ). We applied these eligibility criteria to the RW population to allow better comparisons between the MOSAIC trial and the RW study. However, we were unable to compare performance scores since they are not routinely collected in daily practice.
Of the 281 patients who received FL ? oxaliplatin, 200 met the MOSAIC eligibility criteria (eligible RW oxaliplatin patients) and 43 did not (ineligible RW oxaliplatin patients). Of the 110 patients who received FL only, 54 met the eligibility criteria (eligible RW FL-only patients) and 32 did not (ineligible RW FL-only patients). A total of 62 patients could not be classified because of missing CEA values and they were excluded from further analysis. In total, 67 % of these missing values were found in just four hospitals, where CEA levels were not routinely measured. The most important reasons for ineligibility in the FL ? oxaliplatin group were chemotherapy not starting within 7 weeks and high CEA levels. In the FL-only group the most important reason was age above 75 years.
The differences between RW FL ? oxaliplatin and RW FL-only patients regarding reasons for MOSAIC trial ineligibility resulted from the non-randomised assignment of the treatments in the Dutch observational study. Physicians in daily practice appeared to be reluctant to prescribe oxaliplatin to older patients. As a consequence, the baseline characteristics of RW patients receiving FL ? oxaliplatin were different from those of RW patients receiving FL only. Differences amongst the RW-eligible patients were also found: eligible RW oxaliplatin patients were significantly younger and had fewer comorbidities than eligible RW FL-only patients [18] . In contrast, eligible RW oxaliplatin patients had the same median age as the patients included in the MOSAIC trial (both 61 years) and also ineligible RW oxaliplatin patients showed a comparable median age (62 years), indicating that physicians probably considered comparable kinds of patients for inclusion in the MOSAIC trial and adjuvant treatment with oxaliplatin in RW practice. Regarding other baseline characteristics, such as age, depth of invasion, number of involved nodes and tumour differentiation, which were considered not related to treatment assignment, we did notice some baseline differences (Table 1) . However, given their relatively mild prognostic value in differing directions, we expected a comparable baseline prognosis of the MOSAIC trial patients and RW-eligible oxaliplatin patients. However, RW-ineligible oxaliplatin patients were expected to have a worse baseline prognosis because of their significantly higher CEA values, which is an important unfavourable prognostic factor [21] . Similarly, we expected patients receiving FL only (both RW-eligible and ineligible FL-only patients) to have a more favourable baseline prognosis than MOSAIC trial and RW-eligible oxaliplatin patients since they had significantly lower percentages of elevated CEA levels.
In conclusion, MOSAIC trial patients and eligible RW patients receiving FL ? oxaliplatin were expected to have a comparable baseline prognosis while all other RW patients were expected to have a different baseline prognosis.
Disease-Free and Overall Survival Outcomes
The MOSAIC trial patients randomised in the FL ? oxaliplatin arm had a significantly improved 5-year DFS compared to the patients receiving only FL (HR 0.78, p = 0.005, Table 1 ). In RW patients, a comparison of these treatments could not be made directly because of incomparability of the RW FL-only and RW FL ? oxaliplatin groups caused by the reluctance of physicians to use FL ? oxaliplatin in older patients with more comorbidity (see previous section). In the RW study, the FL-only patients (both eligible and ineligible) had an even better 2-year DFS than all other groups, which can probably be largely explained by the significantly lower percentage of patients with elevated CEA levels ( Table 1) . In an attempt to correct for this incomparability when estimating the 2-year DFS of FL ? oxaliplatin versus FL in the RW-eligible patients, different adjustment methods were applied to the Cox multivariate regression model, such as average covariate adjustment, regression adjustment on propensity scores and propensity score-matched survival analysis. However, these models failed to produce meaningful results since the sample size was not powered for this purpose. This, in combination with missing data on potentially other unmeasured confounding variables, resulted in possibly biased estimates with wide confidence intervals [20] .
Regarding the comparison of MOSAIC trial patients receiving FL ? oxaliplatin and eligible RW patients receiving FL ? oxaliplatin, comparisons were considered justified and showed comparable 2-year DFS results of 79.5 and 78.4 % respectively (p = 0.32). As expected, the 2-year DFS was significantly worse in ineligible RW patients receiving FL ? oxaliplatin (56.7 %, p \ 0.01) [18] . This can probably be largely explained by the significantly higher CEA levels that were present in these ineligible RW oxaliplatin patients compared to eligible RW oxaliplatin patients. Conclusions regarding the 2-year OS were comparable with those for DFS.
DFS results from 2 to 5 years and OS results from 2 to 6 years were available for the MOSAIC trial population (Table 1) .
Model Structure
A Markov model was developed to estimate the clinical and cost consequences of oxaliplatin over the remaining lifetime of the patients. The model simulated the transition of patients receiving adjuvant chemotherapy for stage III colon cancer through three health states that are typically observed in a clinical setting: alive without relapse, alive following relapse and dead. For all scenarios, the primary health economic outcome was the marginal cost per quality adjusted life-year (QALY) gained for oxaliplatin combined with FL versus FL alone. Figure 1 provides an overview of the health economic model. A similar model was used by Pandor et al. [22] .
Transitions between health states were derived from (disease-free) survival curves using a 3-month cycle length, which was considered short enough to avoid multiple transitions between health states within a single cycle. The assumptions that underpin the health economic analysis are presented in Table 2 . Future cost and benefits were discounted at a rate of 4 and 1.5 %, respectively, consistent with current Dutch guidelines [23] . The Markov model was validated by comparing the model results to the results observed in the MOSAIC trial and in RW patients. The Markov model was developed using decision analysis software (TreeAgePro 2009 5Suite, release 1.2, TreeAge software, Inc, Williamstown, MA, USA).
Model scenarios
Cost-effectiveness analyses were performed for three different scenarios: (1) CEA based on MOSAIC trial patients only; (2) CEA using MOSAIC trial patients and eligible RW patients; (3) CEA using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had an equal effect in ineligible and eligible patients; (4) CEA using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had no effect amongst ineligibles (Table 3 ).
Model Input: Clinical Effectiveness
The transition probabilities related to relapse and death are time-dependent variables in which transitions take place every 3 months. Patients in the ''alive without relapse'' state may stay in that phase (tp1), relapse (tp2) or die (tp5). Patients in the ''alive following relapse'' state may stay in that phase (tp3) or die (tp4).
Scenario 1
In scenario 1, tp1 was solely based on the published MOSAIC 5-year DFS Kaplan-Meier (KM) curves of both treatment groups [19] . The cumulative DFS probabilities were read from the published KM figure and converted to transition probabilities using the following formula: p t = P t /P t -1, where P t and P t -1 denote the cumulative probability of surviving at the end of times t and t -1, respectively; pt denotes the transition probability for time t. After 5 years, the probability of relapse (tp2) was assumed to be zero. During the MOSAIC trial (up to 4 years of follow-up), 28 of the 1,347 (2 %) randomised patients died without having relapsed [13] . These deaths were equally distributed among both treatment groups and thus seemed independent from prescription of oxaliplatin [5] . We used this percentage to calculate tp5 over the first 4 years. Beyond this period, we assumed that the patients in our model have the same background mortality as an age-matched population of Dutch individuals with no history of colon cancer. Dutch vital statistics were used to calculate tp5 after 4 years [24] .
Mortality rates amongst patients in the relapsed state (tp4) were based on published MOSAIC overall survival KM curves, which showed the probability of surviving up to 7 years after randomisation [19] . However, the probability of dying without relapse was also included in the published KM figure. In order to arrive at tp4, we subtracted tp5 from the OS curves. We assumed tp4 after 7 years to equal background mortality (tp5).
Scenario 2
In scenario 2 the FL alone arm was modelled as in scenario 1. In the FL ? oxaliplatin arm, results from eligible RW patients receiving FL ? oxaliplatin were added. Transition probabilities in the FL ? oxaliplatin arm were based on both the MOSAIC trial (see scenario 1) and the 2-year DFS and OS KM curves of eligible RW patients. At each time point, the transition probabilities from the MOSAIC trial and RW patients were combined via meta-analysis. For all transition probabilities, Q statistics were negative and a fixed effect model could be used. Inverse variance weighted pooled transition probabilities and pooled standard errors were calculated accordingly [25] . Since in RW patients only 2-year DFS and OS KM curves were available, transition probabilities beyond 2 years were taken from the MOSAIC trial.
Scenario 3 and 4 Scenario 3 and 4 incorporated
ineligible patients who comprised 18 % of the RW oxaliplatin patients. To reflect Dutch RW clinical practice of patients receiving FL ? oxaliplatin, 82 % of the cohort was modelled as if it was eligible, and 18 % as if it was ineligible for the MOSAIC trial. The eligible cohort was modelled according to scenario 2.
For ineligible patients receiving FL ? oxaliplatin, transition probabilities up to 2 years were derived from the 2-year DFS and OS Kaplan-Meier curves derived from RW ineligible oxaliplatin patients. Like in scenario 2, all transition probabilities beyond 2 years were derived from the MOSAIC trial. However, ineligible patients had a worse prognosis than the eligible MOSAIC trial patients, so transition probabilities beyond 2 years could not be taken directly from the MOSAIC trial. We therefore used the following two-step approach. We first adjusted the 3-monthly transition probabilities to match the worse prognosis of the ineligible RW oxaliplatin patient population. Comparisons of the 2-year DFS curves of eligible and ineligible RW oxaliplatin patients revealed that the 3-monthly transition probability of relapse was on average three times higher amongst the ineligible patients than it was amongst the eligible patients. Since this ratio was relatively constant over the 2-year period for which data were available, we assumed that this ratio would remain at this level beyond 2 years and therefore multiplied the Fig. 1 Schematic of the health economic model Table 2 Model assumptions All relapses were assumed to occur within 5 years following resection of the primary tumour. Clinical evidence from long-term follow-up of patients undergoing adjuvant chemotherapy supports this assumption [39] All deaths due to colon cancer were assumed to occur within 7 years following resection of the primary tumour This assumption follows the assumption of unlikely relapses after 5 years and a limited life expectancy after relapse [40] The patients in the model were assumed to have the same background mortality as an age-matched population of Dutch individuals with no history of colon cancer Follow-up duration was assumed to last for 5 years and the 3-monthly costs for monitoring visits and diagnostic tests after the first 2 years were assumed to be €147. Both assumptions are consistent with Dutch guidelines [33] Patients who relapsed were assumed to receive fluoropyrimidines, oxaliplatin and/or irinotecan in different treatment lines as found in a Dutch observational study involving metastatic patients [20, 36] transition probabilities taken from the MOSAIC trial (tp2) by three. Regarding mortality amongst patients in the relapsed state (tp4), there was no difference between eligible and ineligible RW oxaliplatin patients. In scenarios 3 and 4, the FL alone arm was modelled as in scenario 1 and 2. However, given the worse prognosis of the 18 % ineligible RW oxaliplatin patients, transition probabilities for the ineligible FL-only patients were estimated using different assumptions regarding the position of the DFS and OS KM curves for these patients in two scenarios (3 and 4).
Scenario 3
In scenario 3 we assumed that the addition of oxaliplatin to FL would be as beneficial in ineligible patients as in eligible patients. In the MOSAIC trial, the hazard ratios of DFS and OS were 0.78 and 0.80, respectively, for both FL-only and FL ? oxaliplatin patients (Table 1) . To obtain transition probabilities for an ineligible FL-only arm, we applied these hazard ratios to the transition probabilities of the ineligible FL ? oxaliplatin group.
Scenario 4
In scenario 4 we assumed that the addition of oxaliplatin to FL would not have any added benefit in ineligible patients. The transition probabilities for the ineligible FL-only cohort were made equal to the transition probabilities of the ineligible RW patients treated with FL ? oxaliplatin.
Model Input: Health State Utilities
Health utility scores were not collected in either MOSAIC or RW patients. Modelled survival estimates were adjusted to account for the patients' health-related quality of life using published colorectal cancer utility estimates. Like in the analysis of Eggington et al., a utility score of 0.7 was assigned to patients receiving adjuvant treatment who experienced no significant adverse events, while patients who suffered significant adverse events were assigned a utility score of 0.63 for the duration of the treatment course [16, 26] . The percentage of patients experiencing significant adverse events was taken from the observational study and estimated to be 56 % of the RW patients treated with FL only and 65 % of the RW patients treated with FL ? oxaliplatin. An adverse event was considered significant if it led to a dose modification of the adjuvant chemotherapy regimens. Patients who remained diseasefree following adjuvant treatment were assigned a utility score of 0.92, while patients who relapsed were assigned a utility score of 0.24 [26, 27] . Details on how these utility scores were derived can be found in ESM I. 
Model Input: Cost
This health economic analysis was conducted using a hospital's perspective. Resource use was based on RW patients and included patient level chemotherapy usage, inpatient hospital days (associated with administration of treatment and/or serious adverse events), outpatient visits, daycare treatments, laboratory services, imaging services, radiotherapy, surgical and other procedures, and concomitant medications (prophylactic with chemotherapy, and for the treatment of adverse events). The unit cost calculations of inpatient hospital days, outpatient visits and daycare treatments were based on detailed microcosting studies reflecting full hospital costs, including overhead costs [28, 29] . The resource use of surgical procedures, laboratory services and imaging services was valued using the fees as issued by the NZa [30] . Unit cost of chemotherapy and concomitant medications were acquired from the Pharmacotherapeutic Aid Committee [31] . Costs were reported in 2012 euros. Where necessary, costs were adjusted to 2012 using the general price index from the Dutch Central Bureau of Statistics [32] .
Cost of Adjuvant Treatment
In the model, three costing periods could be distinguished. First, cost of the adjuvant treatment period, i.e. costs incurred from first administration of chemotherapy until 30 days after the last administration. These costs were assigned to the first cycle of the model. Mean total cost of adjuvant treatment with FL only was calculated at €5,369 (SD €3,302). Mean treatment cost of FL ? oxaliplatin was €20,861 (SD €8,555) [20] . Although these cost estimates came directly from RW patients and therefore, like the effectiveness estimates, are subject to bias, we found that the mean total treatment costs were not associated with age or comorbidities. For this reason we could directly use these cost estimates in the model.
Cost of Follow-up
Second, the costs of follow-up were assigned to subsequent cycles, in the ''alive without relapse'' health state. The follow-up duration was assumed to last for 5 years. Three-monthly cost of €596 (SD €927) was applied over the first 2 years of follow-up. This estimate was directly derived from the RW patients and found to be independent of type of adjuvant treatment. In subsequent cycles, from year 3-5, no data from RW patients were available. Here, a 3-monthly cost of follow-up of €147 was assumed. This was based on expected resource use according to current Dutch guidelines [33] .
Cost of Relapse
The third period included costs associated with the health state ''alive following relapse''. The treatment of relapsed disease was assumed to be independent of adjuvant treatment. The costs associated with relapse were taken from a related Dutch observational study evaluating patients with advanced colorectal cancer. Patients in this study were treated with FL, oxaliplatin and/or irinotecan in different treatment lines. Mean total cost was estimated at €24,814 (SD €16,967) per patient. The mean survival of these patients was 466 days, resulting in a 3-monthly cost of €4,872 [20] . This cost estimate was applied to the ''alive following relapse'' health state. More information on the calculation of all cost inputs can be found in ESM II.
Sensitivity Analysis
For each scenario, a number of univariate sensitivity analyses were performed to examine the impact of alternative parametric assumptions on the cost-effectiveness estimate. First, zero discount rates for cost and health outcomes were applied. Next, we studied the alternative assumption of having relapse rates beyond 2 years in the ineligible patient cohort that equal the relapse rates of the eligible patients (instead of multiplying this rate by three). Subsequently, alternative utility scores for patients who remained disease-free and suffered a relapse were used. Furthermore, assumptions concerning the choice for FL ? oxaliplatin regimen used (FOLFOX versus CAPOX) were made as well as assumptions concerning the impact of recent guideline changes on the use of cytotoxic regimens for metastatic disease. Alternative percentages of RW patients being eligible for the MOSAIC trial were also applied. Next we conducted one-way sensitivity analyses to explore the impact of alternative durations over which patients may relapse or die from colon cancer on costeffectiveness estimates, as well as the impact of assuming a 7-year time horizon for the evaluation of cost and health outcomes.
Probabilistic sensitivity analysis was undertaken to allow the effects of the joint uncertainty across all input parameters. Each model parameter was assigned a unique probability distribution based upon estimates of uncertainty. Bootstrapping was used to reflect the distribution in treatment costs, sampling from the RW patient data. Table 4 contains an overview of the input parameters and their corresponding distributions.
Monte Carlo sampling techniques were used (10,000 repeated random samples) to generate distributions of lifetime cost and health outcomes for patients treated with FL ? oxaliplatin versus FL alone, for each scenario. Per scenario, the results of the probabilistic sensitivity analysis are presented as confidence intervals surrounding the base case values, incremental cost-effectiveness planes and acceptability curves.
Results
As illustrated in Fig. 2 , the output of the Markov model matched the results of the MOSAIC trial and the RW patients adequately based on face validity. That is, the 2-year and 6-year survival probabilities of the modelled treatment arms in scenarios 1 and 2, and the 2-year survival probabilities of the modelled ineligible oxaliplatin cohort, as can be derived from the curves presented in Fig. 2 , are very similar to the survival rates observed in the MOSAIC trial and the RW observational study, which are presented in Table 1 . Table 5 presents the expected discounted and undiscounted cost and health outcomes for each of the four scenarios. Estimates of the LYs are shown in parentheses. For all scenarios, Table 5 shows that the addition of oxaliplatin to FL is expected to result in increased costs but also additional QALYs given a lifetime horizon. In scenario 1, oxaliplatin showed an incremental QALY gain of 1.02 and an incremental cost of €9,961; the results in scenario 2 were similar, with an incremental QALY gain of 1.13 and incremental cost of €11,055. The corresponding incremental cost-effectiveness ratios in these two scenarios were very similar as well (€9,766 and €9,783, respectively). This was as expected given the comparable populations used in these scenarios. Scenarios 3 and 4 also included RW patients who would not have been eligible for the MOSAIC trial. The assumption of a similar treatment effect of oxaliplatin in this ineligible proportion (scenario 3) resulted in a QALY gain of 1.17, incremental cost of €9,814 and an incremental costeffectiveness ratio of €8,388, which is beneficial when compared to the results from scenario 1 and 2. This can be explained by the worse life expectancy of ineligible patients. In scenario 4, where no effect of oxaliplatin was assumed in ineligible patients, we found a lower overall incremental QALY gain of 0.93 against incremental cost of €11,854, which resulted in an incremental cost-effectiveness ratio of €12,746. The ICERs are only marginally influenced by discounting. Table 6 presents the results of the one-way sensitivity analysis. The sensitivity analysis suggests that all alternative assumptions resulted in some variability in the cost- FL fluoropyrimidines, tp transition probability, RW real world, HR hazard ratio, DFS disease-free survival, OS overall survival, SD standard deviation a SD presented for illustrative purposes only effectiveness estimates. Reducing the time horizon to 7 years resulted in a large increase in ICERs in all scenarios. The cost-effectiveness of oxaliplatin in all scenarios was also sensitive to the treatment cost of FL ? oxaliplatin (FOLFOX versus CAPOX). Furthermore, the ICERs in all scenarios were sensitive to the parameters regarding the hazard ratio for disease-free survival, while only in scenario 4 the increase in cost per QALY was particulartly sensitive to the percentage of patients being eligible for the MOSAIC trial. The ICERs are only marginally influenced by the values of the other parameters, which included relapse rates beyond 2 years of ineligible patients, the utility of being disease-free and in relapse, the cost of relapse, and the assumed time period during which relapses and death due to colon cancer may occur. Figure 3 presents cost-effectiveness planes for all scenarios, showing the marginal cost and QALYs associated with FL ? oxaliplatin in comparison to FL alone. In all scenarios, the addition of oxaliplatin is expected to produce greater health gains than FL only, albeit at a greater cost, in most of the 10,000 simulations. Considering all four scenarios, the 95 % confidence intervals of the incremental cost (generated from the simulations) varied from -€13,958 to €30,876 (Table 5 ). In scenarios 1-3, the 95 % confidence intervals of the incremental QALYs varied from 0.07 to 2.17. Scenario 4 is the only scenario that resulted in a minimum value that was less than 0 (-0.10). This is as expected because this scenario assumed no treatment benefit from oxaliplatin for the ineligible RW patients, which comprised 18 % of the population.
Sensitivity Analysis
Cost-effectiveness acceptability curves are shown per scenario in Fig. 4 to facilitate conclusions about the costeffectiveness of oxaliplatin at different willingness-to-pay thresholds. For example, at a willingness-to-pay threshold of €50,000, there was a probability in scenarios 1-3 of more than 90 % that the addition of oxaliplatin would be cost-effective. This percentage was 86 % in scenario 4.
Discussion
The increasing number of expensive drugs is making it extremely difficult for health care systems to strike an optimal balance between ensuring timely access to these 'promising' drugs and having sufficient evidence of their comparative benefits and risks. Dutch policy regulations allow early conditional access for these expensive drugs, but require the estimation of RW cost-effectiveness using RW data after 4 years.
In our analysis, the RW cost-effectiveness of FL ? oxaliplatin versus FL alone in the adjuvant treatment of colon cancer was estimated by combining the MOSAIC clinical trial with data from a Dutch observational study in a Markov model. We found certain differences but also Fig. 2 Model validation; undiscounted results from modelled overall survival, by scenario and treatment group great similarities between trial and RW patients and incorporated these findings in different model scenarios. This article illustrates how one could design and implement a real-world cost-effectiveness study to yield internally valid results that could also be generalisable. The ICERs of the different scenarios all suggest that FL ? oxaliplatin versus FL alone is cost-effective in the adjuvant treatment of stage III colon cancer.
In scenario 1, clinical effectiveness was modelled based on just the MOSAIC trial. In this scenario incremental QALYs gained with the addition of oxaliplatin were estimated at 1.02 at a discount rate of 1.5 %. Five other CEAs based on the MOSAIC trial have been published [12] [13] [14] [15] [16] . Comparing the QALY estimates, all were very similar to ours, with incremental differences between the two arms of 0.64 in the Canadian model, 0.75 in the US model, 0.76 in the Japanese model and 0.68 and 1.33 in two UK models. The differences mainly resulted from the different discount rates in the analyses (5, 3, 3, 3.5 and 1.5 % in the Canadian, US, Japanese and the two UK models, respectively) [12] [13] [14] [15] [16] .
In our model, cost calculations were based on Dutch RW resource use and unit costs, resulting in incremental total cost of €9,961 at a discount rate of 4 % in scenario 1. Other published models also used country-specific unit cost, but resource utilisation estimates were mainly informed from the MOSAIC trial [5] . Reported incremental costs were €10,779, €13,370, €11,041, €4,969 and €6,763 in the Canadian, US, Japanese and two UK models, respectively (country-specific currencies converted to 2012 euros). Differences resulted from relative differences in price and administration of FL ? oxaliplatin versus FL only and differences between countries in costs postrelapse, which were also sensitive to differences in discount rates (5, 3, 3, 3.5 and 6 %, respectively).
In scenario 1, the resulting ICER was €9,766 per QALY gained. In the Canadian, US, Japanese and UK evaluations, the reported ICERs per QALY gained were €18,986, €17,898, €14,438, €7,309 and €4,518, respectively. All studies concluded that adding oxaliplatin to the adjuvant treatment with FL in patients with stage III colon cancer was cost-effective.
However, the effectiveness results of all these evaluations, including scenario 1 of our study, were based on a clinical trial. The use of results from clinical trials always raises the question of external validity. Are the benefits seen by patients in the clinical trial (efficacy) applicable to patients treated in routine practice (effectiveness)? We made use of the internal validity provided by the randomised design of the MOSAIC trial, while taking external validity into consideration by incorporating effectiveness results from RW patients in scenarios 2-4 of our model. We examined RW patients included in a Dutch populationbased observational study to see how many patients fulfilled the MOSAIC trial eligibility criteria. A total of 82 % of the RW patients receiving oxaliplatin fulfilled these criteria and were added in scenario 2. The resulting base case ICER of €9,783 was very similar to the results of scenario 1. In scenarios 3 and 4, the 18 % of the patient population that did not meet the MOSAIC trial eligibility criteria was added to the model. The resulting ICERs per QALY gained were €8,388 and €12,746 for scenario 3 and 4, respectively, which all suggest the cost-effectiveness of oxaliplatin in the real world. The value of scenarios 3 and 4 is that they focus on estimating the cost-effectiveness of oxaliplatin in the most relevant population: all stage III colon cancer patients who are treated with oxaliplatin in Dutch RW practice. In the RW population-based observational study, all patients treated with FL ? oxaliplatin in 2005 and 2006 in 19 representative hospitals were included (n = 281). Apart from 14 % (n = 38) of patients with missing CEA values, which were considered to occur completely at random, these patients were all taken into account in scenarios 3 and 4. Based on this we believe that our results are generalisable to Dutch RW practice.
However, it is possible that physicians will be steadily less reluctant to prescribe oxaliplatin to older patients. If this happens, the target population (of patients in the future) will be broader than the population we considered (i.e. only patients who received oxaliplatin in 2005 and 2006) , which would reduce the generalisability of our present results. The probability of limited generalisability due to temporal changes in the patient population is particularly present in case new medicines face a slow uptake. However, in our study we do not expect this since we know that most physicians began to use FL ? oxaliplatin as standard treatment soon after the guideline changed in early 2005. This rapid adoption is most likely due to the extensive experience that physicians already had using oxaliplatin in advanced colorectal cancer [34] . Moreover, during 2005 and 2006 we did not observe any changes in the types of patients receiving oxaliplatin and even now there is no strong evidence to support the use of adjuvant treatment with oxaliplatin in the elderly [35] .
In the RW observational study, 82 % of the patients receiving oxaliplatin and 63 % of the patients receiving FL only were eligible for the MOSAIC trial. These percentages are similar to other expensive oncology medicines, where substantial percentages of patients treated with these new drugs would not have fulfilled the pivotal clinical registration trial eligibility criteria [36] . Therefore, CEAs of new, expensive medicines based only on trial data run the risk of not being applicable to the RW population that is actually treated with these medicines; they are in fact cost-efficacy analyses and not cost-effectiveness analyses.
In this cost-effectiveness analysis we took the relative treatment effect of oxaliplatin directly from the MOSAIC trial because of its randomised study design. Subsequently we concluded that the eligible RW oxaliplatin population was sufficiently comparable to the MOSAIC trial population, based on eligibility, baseline characteristics, the way treatments were given and the treatment outcomes (Kaplan-Meier curves). We therefore felt that the relative treatment effect of oxaliplatin observed in the MOSAIC trial would also be expected in the eligible RW oxaliplatin-treated patients. We did notice some differences in baseline prognostic factors between MOSAIC patients and RW-eligible patients, such as depth of invasion, number of involved nodes and tumour differentiation. However, we expect that these differences do not translate into systematic differences in the underlying baseline prognosis and/or the relative treatment effect of oxaliplatin since subgroup analyses of the MOSAIC trial showed that the treatment effect (measured as reduced risk of relapse) was consistent in all subgroups defined using various baseline prognostic factors [5] . Next to this, the full 95% confidence interval of the trial-based hazard ratio (HR 0.78, 98 % CI 0.65-0.93) was considered in the univariate and probabilistic sensitivity analyses, which resulted in maximal ICERs of €32,280 and €27,037 in scenarios 1 and 2, respectively.
Additional assumptions were made in scenarios 3 and 4 regarding the baseline prognosis and treatment effect of oxaliplatin for the ineligible RW oxaliplatin patients. The lower 2-year DFS and OS rates of ineligible RW Fig. 3 Cost-effectiveness planes for FL ? oxaliplatin versus Fl alone, by scenario Fig. 4 Cost-effectiveness acceptability curves for FL ? oxaliplatin versus FL alone, by scenario oxaliplatin patients can largely be explained by the higher percentage of patients in the ineligible RW oxaliplatin with abnormal CEA values. Projections beyond 2 years were uncertain, but alternative assumptions did not impact the ICER results in the univariate sensitivity analysis. We varied the expected treatment effect of oxaliplatin among ineligible RW patients using a base case (scenario 3) and a worst case (scenario 4) scenario. In the base case scenario, an equal relative effectiveness as in the MOSAIC trial was assumed. This is based on subgroup analyses of the MOSAIC trial that showed a positive but statistically nonsignificant effect of oxaliplatin in patients with elevated CEA levels [5, 19] . The worst case scenario involved a zero treatment effect for patients who were ineligible for the MOSAIC trial. This was viewed as a worst case scenario since it is very unlikely that oxaliplatin would be harmful for patients with elevated CEA levels as oxaliplatin is known to have be beneficial in the treatment of advanced colon carcinoma [8] .
There were several study limitations. First, no comparable data from RW patients treated with FL only were available because of the rapid adoption of oxaliplatin in early 2005. An effort was made to correct for the resulting differences between the patients treated with FL only versus FL ? oxaliplatin, but this was hampered by the low number of eligible RW patients treated with FL only (n = 54) and a median follow-up time of only 2 years, which appeared to be the maximum achievable duration given the limited study timeframe of 4 years of conditional reimbursement [36] .
But even without power problems, it would have been uncertain whether correction led to results that were valid, since the potential for bias on unmeasured baseline characteristics cannot be ruled out. RW patients receiving FL only in 2004, just before oxaliplatin became indicated, i.e. historical control patients, might be useful in this context. However, since the MOSAIC patients were very similar to the eligible RW patients treated with FL ? oxaliplatin, we don't expect this to alter the ICER results significantly.
Second, the availability of relevant utility values for the calculation of QALYs was limited. We believe that the evaluation presented here used the best available data; the results of the sensitivity analysis suggest that the effect of this parameter on long-term results is modest.
A third possible limitation is that we did not correct for possible differences in baseline prognostic factors when using cost data from RW patients for both treatment groups. This might have resulted in less valid cost comparisons. However, we found that the treatment costs were not associated with baseline characteristics such as age and comorbidities. Moreover, treatment costs were already incurred within the first 6 months and appeared to be independent of a patients' prognosis. For these reasons we don't expect this limitation to influence the ICER results.
Our effectiveness estimate was based on RW patients combined with only one trial. The MOSAIC trial was the clinical registration trial based on which treatment with FL ? oxaliplatin became indicated for the treatment of stage III colon cancer in the Netherlands. When the costeffectiveness model was built, only one other trial investigating FL ? oxaliplatin versus FL only was available [37] . However, dosing schemes used in that trial are not seen in Dutch RW practice. We therefore decided not to use this trial in our model. Recently, a third trial was published [38] . Efficacy results of the MOSAIC trial were comparable to the results presented in the other two trials. Incorporating these trials into our analysis would have resulted in similar ICERs, which would only support the conclusion of its cost-effectiveness.
Lastly, modelling in CEAs always requires various assumptions. In all scenarios, univariate and probabilistic sensitivity analyses indicated that the ICERs are acceptable and robust under a wide range of model assumptions.
Conclusions
The requirement in Dutch policy for RW cost-effectiveness estimations using patients treated in daily clinical practice will result in the application of different methods that aim to prove internally valid estimations, but also focus on the generalisability of the results in Dutch RW practice. This can result in better evidence by addressing uncertainty in outcomes arising from the gap between clinical trials and everyday practice. In this study we combined data from a Dutch observational study with the pivotal clinical registration trial. We expect that this approach can be used in determining the RW cost-effectiveness of other expensive medicines. In conclusion, the ICERs of the different scenarios are all acceptable and support the use of oxaliplatin in the adjuvant treatment of stage III colon cancer in the Netherlands.
